Alpha Tau to Participate in Citi’s 2023 Healthcare Services, Medtech, Tools & HCIT Conference
February 21 2023 - 3:00PM
Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ("Alpha Tau," or the
“Company”), the developer of the innovative alpha-radiation cancer
therapy Alpha DaRT™, announced today that the Company plans to
participate in Citi’s 2023 Healthcare Services, Medtech, Tools
& HCIT Conference on March 1, 2023 taking place at Citi HQ
Conference Center in New York City.
Citi’s 2023 Healthcare Services, Medtech,
Tools & HCIT
Conference:Date:
Wednesday, March 1, 2023Location: Citi HQ
Conference Center
If you would like to schedule a 1:1 meeting, please
contact your Citi representative.
About Alpha DaRT™
Alpha DaRT (Diffusing Alpha-emitters Radiation
Therapy) is designed to enable highly potent and conformal
alpha-irradiation of solid tumors by intratumoral delivery of
radium-224 impregnated sources. When the radium decays, its
short-lived daughters are released from the sources and disperse
while emitting high-energy alpha particles with the goal of
destroying the tumor. Since the alpha-emitting atoms diffuse only a
short distance, Alpha DaRT aims to mainly affect the tumor, and to
spare the healthy tissue around it.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli medical
device company that focuses on research, development, and potential
commercialization of the Alpha DaRT for the treatment of solid
tumors. The technology was initially developed by Prof. Itzhak
Kelson and Prof. Yona Keisari from Tel Aviv University.
Investor Relations
ContactIR@alphatau.com
Alpha Tau Medical (NASDAQ:DRTS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Alpha Tau Medical (NASDAQ:DRTS)
Historical Stock Chart
From Jul 2023 to Jul 2024